Publications by authors named "P Pichotta"
A review of a family of ultra-rapid-acting insulins: formulation development.
J Diabetes Sci Technol
July 2012
Article Synopsis
- The review discusses the development of ultra-rapid-acting recombinant human insulin formulations, specifically focusing on the use of EDTA to enhance absorption and onset of action compared to traditional insulins.
- Initial trials with the formulation BIOD-090 showed faster absorption than regular human insulin, but resulted in more injection site pain, leading to the development of a next-generation formulation, BIOD-100, which improved patient tolerability.
- Further innovations, including adjustments with calcium and magnesium sulfate in newer formulas (BIOD-125 and BIOD-123), have aimed to enhance tolerability while maintaining rapid action profiles in hopes of improving overall patient experience.
Aims: VIAject® is a formulation of human insulin with a very fast onset of action. Previous studies used VIAject in a concentration of 25 U/ml and a pH of 4 [VIAject 25 (VJ25)]. Objective of this double blind, three-way crossover study was to compare the pharmacodynamic/pharmacokinetic properties of a novel formulation of VIAject with a concentration of 100 U/ml and a neutral pH [VIAject 7 (VJ7)] with VJ25 and insulin lispro (LIS).
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess how different types of insulin (VIAject, human regular insulin, and insulin lispro) impact blood flow and oxidative stress after meals in type 2 diabetes patients.
- VIAject significantly lowered post-meal levels of markers for oxidative stress (ADMA and nitrotyrosine) compared to the other insulin types, suggesting it may be more beneficial for managing oxidative stress.
- Additionally, VIAject led to quicker improvements in microvascular blood flow and skin oxygenation after meals, indicating enhanced endothelial function compared to human insulin and insulin lispro.
Background: Sevoflurane has a lower blood:gas partition coefficient than isoflurane, which may cause a more rapid recovery from anesthesia; it also might cause faster emergence times than for propofol-based anesthesia. We evaluated a database that included recovery endpoints from controlled, randomized, prospective studies sponsored by Abbott Laboratories that compared sevoflurane to isoflurane or propofol when extubation was planned immediately after completion of elective surgery in adult patients.
Methods: Sevoflurane was compared to isoflurane in eight studies (N=2,008) and to propofol in three studies (N=436).
The pharmacokinetic and safety profiles of clarithromycin (C) and its 14-hydroxy-clarithromycin (HC) metabolite were determined after a multiple-dose oral clarithromycin regimen (250 mg twice daily for five doses) in six healthy subjects and seven patients with moderate or severe hepatic impairment (Pugh grades B and C). Plasma and urine C and HC concentrations were determined using high-performance liquid chromatography. Hepatic impairment resulted in increased harmonic mean C terminal disposition half-life and mean +/- SD C renal clearance (CLR) compared with normal volunteers (5.
View Article and Find Full Text PDF